p-Tau217 in Alzheimer's Disease Research

Phosphorylated Tau at threonine 217 (p-Tau217) is a soluble fragment of hyperphosphorylated Tau protein that can be detected in the bloodstream. In Alzheimer's disease research, p-Tau217 levels reflect cerebral amyloid and Tau pathology, showing strong concordance with PET imaging findings. This makes p-Tau217 one of the most intensively studied blood-based biomarkers for AD research applications.

Research Findings on p-Tau217

  • Stronger signal than p-Tau181: Plasma p-Tau217 shows approximately 2–3× greater fold-change between Aβ-positive and Aβ-negative research participants compared to p-Tau181 in published cohort studies.
  • Correlates with Tau PET: Plasma p-Tau217 levels correlate with Tau PET SUVR in Braak-associated brain regions in multiple independent cohorts.
  • Early elevation: p-Tau217 elevations are detectable in cognitively unimpaired Aβ-positive individuals, supporting its use in preclinical AD research.
  • Disease specificity: Published studies report that p-Tau217 can differentiate AD pathology from other neurodegenerative conditions in research settings.
  • Clinical trial utility: p-Tau217 has been incorporated as a screening biomarker in multiple Alzheimer's therapeutic trials to enrich for Aβ-positive participants.

Research Applications

  • Cohort enrichment — identify research participants likely to have cerebral amyloid pathology using a blood draw, reducing need for PET screening in observational and interventional studies.
  • Longitudinal biomarker monitoring — track p-Tau217 trajectories over time to assess pharmacodynamic effects of anti-amyloid and anti-Tau investigational therapies.
  • Population-based research — scalable, cost-efficient blood biomarker for large epidemiological and aging cohort studies.
  • Prognostic research — investigate p-Tau217 as a predictor of cognitive trajectories in longitudinal observational cohorts.
  • Translational studies — support therapeutic development with a blood-based biomarker that reflects target engagement and disease modification.